Drug Development Executive
Clinical/Medical
"Pill Penalty" and Portfolio Prioritization*: For Biotech CMOs and CSOs
0:00
-14:18

"Pill Penalty" and Portfolio Prioritization*: For Biotech CMOs and CSOs

*There are loopholes, apparently

The law of unintended consequences is inescapable! I have summarized the topic in general and have highlighted the recent NEJM opinion article that reflects the mainstream medical view.

Discussion about this episode

User's avatar